- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT03016455
B Cell Lymphocyte in Humoral Rejection and Alloimmunisation (BHL)
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The principal objective is to better understand the B cell dependant mechanisms of the chronic antibody mediated rejection (cAMR). A particular focus will be done on the mechanisms that could explain the natural history of chronic humoral mediated rejection and of pathways from DSA negative status toward DSA positive status and from DSA positive status to histological lesions. The following will be undergone for three categories of patients (stable patients, DSA positive patients without cAMR and DSA positive patients with cAMR) :
- A phenotypic analysis of B cells of patients suffering from chronic humoral rejection or who are simply DSA positive.
- A functional analysis in autologous cultures in order to confirm our preliminary results.
- A functional analysis in a heterologous proliferation test aiming at a better understanding of the absence of B cell regulation of T cell proliferation in patients suffering from cAMR.
- A cytokine analysis (IL10, alpha-tumor necrosis factor, gamma-interferon dosing), for a better understanding of the mechanisms that are involved in the regulation of the T cell response that is induced by the B cells.
Studietyp
Inskrivning (Förväntat)
Kontakter och platser
Studieorter
-
-
-
Amiens, Frankrike, 80054
- Avslutad
- CHU Amiens
-
Angers, Frankrike, 49933
- Avslutad
- CHU Angers
-
Brest, Frankrike, 29200
- Rekrytering
- Chu Brest
-
Caen, Frankrike, 14033
- Avslutad
- CHU CAEN
-
Clermont Ferrand, Frankrike, 63003
- Avslutad
- CHU Clermont Ferrand
-
Limoges, Frankrike, 87042
- Indragen
- CHU Limoges
-
Paris, Frankrike, 75743
- Avslutad
- APHP Hopital Necker
-
Poitiers, Frankrike, 86021
- Avslutad
- CHU Poitiers
-
Reims, Frankrike, 51092
- Avslutad
- CHU Reims
-
Rennes, Frankrike, 35033
- Avslutad
- CHU Rennes
-
Rouen, Frankrike, 76230
- Avslutad
- CHU Rouen
-
Strasbourg, Frankrike, 67091
- Avslutad
- Hôpitaux Universitaires de Strasbourg
-
Tours, Frankrike, 37044
- Avslutad
- CHU Tours
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion criteria :
Non stable patients :
- Patient older than 18 years old.
- Patient which is the recipient of a renal transplant
- Patient who develops anti donor antibodies after the transplantation and / or suffering from a histologically-proven antibody mediated rejection.
- Patient who has signed an informed consent form
Stable patients :
- Patient older than 18 years old.
- Patient that is the recipient of a renal transplant for more than one year
- Patient who has accepted to participate in the Brest Kidney graft recipient collection
- Patient that is not suffering from any rejection, that has a good renal function and a low proteinuria
- Patient that has not developed any DSA.
Exclusion criteria :
- Patients that has not signed the consent form.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
DSA positive patients without cAMR
Presence of DSA w/o cAMR
|
|
DSA positive patients with cAMR
Presence of DSA w/ cAMR
|
|
Stable patients
No DSA No cAMR
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Evaluation of the ratio (percentage and absolute values) of mature LB subpopulations (LBm1 to LBm5) and of memory LB by specific labellings
Tidsram: At the inclusion day
|
At the inclusion day
|
|
Evaluation of the proliferation of freshly isolated cells T in presence of autologous B cells
Tidsram: At the inclusion day
|
At the inclusion day
|
|
Evaluation of the proliferation of T cells in a heterologous test
Tidsram: At the inclusion day
|
aiming at a better understanding of the absence of B cell regulation of T cell proliferation in patients suffering from cAMR
|
At the inclusion day
|
cytokine analysis(IL10, alpha-Tumor Necrosis FActor, gamma-Interferon dosing)
Tidsram: At the inclusion day
|
for a better understanding of the mechanisms that are involved in the regulation of the T cell response that is induced by the B cells.
|
At the inclusion day
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Correlation between phenotypic and functional evaluations, and clinical outcome
Tidsram: One year post inclusion
|
One year post inclusion
|
|
comparison of the B cell subpopulations before and after rituximab treatment
Tidsram: One year post inclusion
|
In a subgroup of patients, the ones that will happen to be treated by rituximab for a rejection episode.
|
One year post inclusion
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Förväntat)
Avslutad studie (Förväntat)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- BHL (RB 12.047)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Njurtransplantation
-
Abramson Cancer Center of the University of PennsylvaniaIndragenCancerpatienter som genomgår stamcellstransplantation (RCT of ACP for Transplant)
-
Novartis PharmaceuticalsAvslutad
-
Universitaire Ziekenhuizen KU LeuvenAvslutadPrevalens av Augmented Renal Clearance | Riskfaktorer för ökad renal clearanceBelgien
-
The First People's Hospital of ChangzhouHar inte rekryterat ännu
-
Andrew B AdamsBristol-Myers SquibbAvslutadMisslyckad renal allograftFörenta staterna
-
Oregon Health and Science UniversityAvslutad
-
Assiut UniversityOkänd
-
Fady M Kaldas, M.D., F.A.C.S.RekryteringBedömer immunsuppressionsmodulering på renal återhämtning efter LTFörenta staterna